Novel tyrosine kinase inhibitors in the treatment of cancer.
Ocana
Alberto
A
Drug Development Program, Princess Margaret Hospital, Toronto, Canada. alberto.ocana@uhn.on.ca
Serrano
Rosario
R
Calero
Raul
R
Pandiella
Atanasio
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases